Skip to main content
. 2023 Oct 3;14:1270981. doi: 10.3389/fimmu.2023.1270981

Table 1.

Characteristic and main findings of the included papers that show an association between ECM remodeling and tumor immune traits.

Ref Molecule Tumor type Year Enrolled Patient Queried Databases Association with immune traits
(28) ABI3BP LUAD 2023 / TIMER, GEPIA, TCGA, HPA (n=504) correlation with B and CD4+ T memory cells, Tregs, B cells, T cells, CD4+ T, DC activation, and Ecs
(29) ADAM12 CRC 2021 / Oncomine, UALCAN, TCGA, GEPIA, TIMER, TISIDB (n=86733) correlation with CD4+ T, B, CD8+ T cells, neutrophils, macrophages, DC
(30) ADAMs PAAD 2020 / TCGA (n=18313) positive correlation with DC, B cells, neutrophils, CD8+ T cells, macrophages
(31) BGN TNBC 2022 / TCGA, GEO (n=116) negative correlation with CD8 + T cells
(32) GC 2022 / TCGA, GTEx (n=407) positive correlation with NK cells and macrophages; negative correlation with Th17 cells
(33) COL10A1 PAAD 2022 / TCGA, GEO, GEPIA (n=182) positive association with CD8+ T cells, M1 and M2 Mac; positive correlation with PD-L1, CTLA-4, CD73, HLA-E
(34) COL5A1 pan-cancer 2022 / Oncomine, TCGA, CCLE, HPA, DNMIVD,cBioPortal association with naive B cells, memory B cells, monocytes, macrophages, CD8+ and CD4+ T cells
(35) COL6A1 RCC 2020 161 / association with PD-L1 expression
(36) COL6A3 PDAC 2020 / TCGA, GEO (n=30) association with CD4+ and CD8+ T, B cells, neutrophils, Mac and CD; association with CTLA-4, PD-1, PD-L1, PD-L2
(37) Collagen alignment BC 2021 / TCGA, GEO negative correlation with anti-tumor T cells
(38) Collagen I BC 2022 30 TCGA, GEO (n=1161) positive association with Th1 and Tregs, negative association with Th1
(39) Collagen I, III, V NSCLC 2021 120 / negative association of Coll I and III with Tregs and of Coll V with NK
(40) Collagen, Elastin BCC 2022 22 / association with TILs counts
(41) CTHRC1 CRC 2022 / TCGA, GEO (n=242) correlation with TAMs, M2 macrophages, Tregs, T cell exhaustion, and MDSCs
(42) GC 2022 / TCGA, GEO, GSA (n=375) correlation with M2 Mac, NK cells, Th1 cells and DC
(43) EMILIN2 CRC 2022 23 TCGA (n=844) negative association with M2 Mac; positive association with M1 Mac
(44) LLG 2021 97 CGGA, TCGA (n=1018) positive correlation with B cells, CD8+ T and CD4+ T cells, DC, Mac and neutrophils
(45) CCC 2022 / TCGA, UCSC Xena (n=531) positive correlation with CTLA-2, PD-1, LAG3, and TIGIT
(46) LOXL3 HCC 2021 / TCGA, TIMER, GTEx (n=52) positive correlation with CD4+ T and CD8+ T cells, B cells, DC, neutrophils, Mac, B cells
(47) LOXL4 HCC 2021 90 / association with PD-L1 expression
(48) MMP1 HCC 2022 / TCGA, TIMER, GEO (n=11104) association with activated DC, Mac, CD4+ T cells and MDSC
(49) MMP9 pan-cancer 2022 / TCGA, GTEx (n=33) positively correlates with T cells, macrophages, Th1 cells, and T cell exhaustion
(50) PCOLCE BC 2021 / METABRIC (n=273) association with PD-1/PD-L1 expression level
(51) pan-cancer 2022 / TCGA, CPTAC, GEO (n=33) positive correlation with CD4+ and CD8+ memory cells, CD4+ T, CD8+ T, NK cells
(52) PLOD2 pan-cancer 2022 / GTEx, CCLE (n=21) negative correlation with memory B cells, activated NK cells, CD8+ T cells,Treg; positive correlation with Mac
(53) SPP1 LUAD 2021 / TCGA, CPTAC (n=551) correlation with low CD8+ Tcell infiltration and high M2-type macrophages
(54) TNC BC 2020 160 / negative correlation with LC3B and CD8+ T cells
(55) BC 2021 219 GEO negative association with macrophages and CD8+ T cells
(56) OSCC 2020 68 GEO positive correlation with CD11+ cells and Tregs
(57) LGG 2022 62 / positive association with MDSC; negative association with effector T cells
(58) Versican NSCLC 2022 / GEO positive association with DC, negative correlation with CD8+ T cells
(59) MPM 2022 / TGCA (n=12) association with PD-1 overexpression and downregulation of CD127
(60) CCa 2010 149 / negative association with CD8+ T cells
(61) MM 2016 19 / negative association with CD8+ T cells
(62) CRC 2017 122 / negative association with CD8+ T cells

BC, breast cancer; MM, myeloma; CCa, cervical cancer; MPM, pleural mesothelioma; CCC, clear cell carcinoma; CRC, colorectal cancer; NSCLC, non-small cell lung cancer; LGG, low grade glioma; OSCC, oral squamous cell carcinoma; LUAD, lung adenocarcinoma; HCC, hepatocellular carcinoma; PDAC, pancreatic ductal adenocarcinoma; PAAD, pancreatic adenocarcinoma.